Review of bosentan in the management of pulmonary arterial hypertension by Gabbay, Eli et al.
© 2007 Dove Medical Press Limited.  All rights reserved
Vascular Health and Risk Management 2007:3(6) 887–900 887
R E V I E W
Review of bosentan in the management 
of pulmonary arterial hypertension
Eli Gabbay1
John Fraser2
Keith McNeil3
1Western Australian Lung Transplant 
Unit and Pulmonary Hypertension 
Service, Royal Perth Hospital, Western 
Australia, Australia; 2Critical Care 
Research Group, The Prince Charles 
Hospital, Rode Road, Chermside, 
Queensland, Australia; 3Transplant and 
Pulmonary Vascular Disease Unit, The 
Prince Charles Hospital, Rode Road, 
Chermside, Queensland, Australia
Correspondence: Eli Gabbay
Western Australia Lung Transplant Unit 
and Pulmonary Hypertension Service, 
Royal Perth Hospital, GPO Box X2213, 
Perth, Western Australia, 6001
Tel + 618 9224 3853
Fax +618 9224 3866
Email Eli.Gabbay@health.wa.gov.an
Abstract: The dual endothelin receptor antagonist, bosentan, is an orally active therapy, which 
is effective in the treatment of pulmonary arterial hypertension (PAH). This review critically 
appraises the evidence for the effi cacy of bosentan in idiopathic and familial PAH, in PAH 
associated with connective tissue disease and in PAH which may develop in association with 
other conditions. Data from the pivotal placebo controlled studies and their open labeled exten-
sions as well as long term survival and quality of life data is presented. Data is also presented on 
the potential benefi t of bosentan in patients with inoperable chronic thromboembolic pulmonary 
hypertension. The safety and tolerability of bosentan as well as drug interactions are discussed. 
Dosage recommendations in adults and pediatrics are presented. An algorithm is provided to 
guide the reader in monitoring potential increases in alanine and aspartate transaminase levels 
that may occur with bosentan use and the dose adjustments that are recommended as a result 
of any increase in the levels of these enzymes are shown. Finally, the role of bosentan as part 
of combination therapy in PAH is examined.
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Introduction
Pulmonary arterial hypertension (PAH) is a condition characterized by dyspnea, 
fatigue, chest pain and syncope (Gaine and Rubin 1998; Runo and Loyd 2003; Galie 
2004; Rubin 2004). PAH results from narrowing of the small arteries and arterioles 
resulting in elevation of pulmonary vascular resistance (PVR), which if left untreated, 
results in the development of right ventricular failure and death.
The pathogenesis that underlies PAH has become better understood. Central to the 
development of PAH is pulmonary vascular endothelial cell dysfunction. The role of 
endothelin as a central mediator in the development of PAH has been demonstrated 
and this has resulted in the development of endothelin receptor antagonists (ERAs), 
which have favorably impacted on symptoms, exercise capacity and prognosis for 
patients with PAH (Humbert, Morrell et al 2004).
Bosentan, a dual endothelin receptor antagonist, is the fi rst ERA to be used suc-
cessfully in the treatment of PAH. This article reviews the evidence for the use of 
bosentan in PAH including it’s effi cacy in various types of PAH, its potential toxicity, 
and associated drug interactions.
Defi nition and classifi cation
Pulmonary hypertension is defi ned as a sustained elevation of mean pulmonary artery 
pressure to a level greater than 25 mmHg at rest or greater than 30 mmHg during 
exercise (Runo and Loyd 2003; Galie 2004; Rubin 2004).
Previously, pulmonary hypertension was defi ned as primary (PPH) or second-
ary (Gaine and Rubin 1998). More recently, a series of World Health Organization 
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sponsored expert conferences suggested replacing this 
simplistic categorization with a new classifi cation (Table 1) 
(Simonneau et al 2004). This classifi cation distinguishes 
pulmonary hypertension via a combination of the underlying 
mechanisms and etiology, and is more useful when consider-
ing the natural history, prognosis and potential therapies of 
this disorder. Most of the therapies that have been utilized in 
pulmonary hypertension have been found to be effi cacious 
in group 1 (PAH) of this classifi cation. In this classifi cation, 
the term primary pulmonary hypertension has been replaced 
by the terms idiopathic pulmonary arterial hypertension and 
familial pulmonary arterial hypertension. Patients with PAH 
(Group 1) have evidence of sustained elevation in pulmo-
nary pressure and additionally have a normal pulmonary 
artery wedge pressure 15 mmHg. Additionally, this group 
excludes patients where the underlying cause of the elevated 
pulmonary pressure is felt to be related to hypoxemic lung 
disease (Group 3), thromboembolic disease of the pulmo-
nary vasculature (Group 4), or miscellaneous other causes 
(Group 5).
Pulmonary hypertension in clinical practice most com-
monly arises as a result of left heart disease (Group 2). It is 
important to note that the therapies discussed in this article 
have not been found to be helpful (and are potentially 
deleterious) in this group of patients. Pulmonary hypertension 
may arise from chronic thromboembolic disease (CTEPH) 
(Moser et al 1990). This condition needs to be excluded 
when a diagnosis of PAH is being considered because treat-
ment of this condition is predominantly surgical, although 
medical therapy may be effective in selected cases (Bresser 
et al 2004; Bonderman et al 2005; Hoeper et al 2005; Rubin 
et al 2006).
Pulmonary hypertension can occur in association with 
lung disease and/or hypoxemia. In these conditions treat-
ment is directed to the underlying cause and correction of 
the hypoxemia although it may yet transpire that the PAH 
specifi c therapies discussed below may have a role in these 
patients (Jones et al 1989; Strange 2005).
Pathogenesis and rationale for PAH 
therapies
A detailed discussion of the pathogenesis of PAH is beyond 
the scope of this article and readers are referred elsewhere 
(Voelkel et al 1997; Humbert, Morrell et al 2004). In sum-
mary, established PAH is characterized by constriction of the 
pulmonary arterioles resulting predominantly from vascular 
Table 1 WHO Classifi cation of pulmonary hypertension (abridged) (Humbert, Morrell et al 2004)
Group1: Pulmonary arterial hypertension (PAH)
 - Idiopathic (IPAH)
 - Familial (FPAH)
 - Associated with (APAH)
  - Collagen vascular disease (connective tissue disease)
  - Congenital systemic-to-pulmonary shunts (Eisenmenger syndrome)
  - Portal hypertension (Portopulmonary hypertension)
  - HIV infection
  - Drugs and Toxins
  - Other (including thyroid disorders, hemoglobinopathies, myeloproliferative disorders, splenectomy)
 - Associated with signifi cant venous or capillary involvement
  - Pulmonary veno-occlusive disease (PVOD)
  - Pulmonary capillary hemangiomatosis (PCH)
 - Persistent pulmonary hypertension of the newborn
Group 2: Pulmonary hypertension with left heart disease
 - Left-sided atrial or ventricular heart disease
 - Left-sided valvular heart disease
Group 3: Pulmonary hypertension associated with lung disease and/or hypoxemia
 - Sleep Disordered Breathing
 - Interstitial Lung Disease
 - COPD
 - Chronic exposure to high altitude
Group 4: Chronic thromboembolic pulmonary hypertension (CTEPH)
Group 5: Miscellaneous
 - Sarcoidosis
 - Histiocytosis X
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remodeling, with variable contributions from vasoconstric-
tion and thrombosis. The role of the characteristic plexiform 
lesions in the pathogenesis and natural history of PAH is 
unclear.
Within the pulmonary arterioles, the main cellular 
changes involve the endothelium, platelets, smooth muscle 
cells and adventitial fi broblast. PAH arises from a complex 
interplay of molecular and genetic abnormalities resulting in 
these cellular changes (Humbert, Morrell et al 2004).
Endothelial cell injury and dysfunction is central to the 
development of the abnormalities seen in PAH, and this 
results in an imbalance in vaso-active mediators normally 
produced by the endothelium. Central to the development 
of PAH is reduced production of prostacyclin (PGI2), nitric 
oxide (NO) and vasoactive intestinal peptide (VIP), with 
upregulation of endothelin 1 (ET-1) (Humbert, Sitbon et al 
2004). The currently available PAH therapies act at least in 
part, by helping redress this imbalance.
Epidemiology and genetics
The incidence and prevalence of idiopathic pulmonary arte-
rial hypertension is uncertain. The reported incidence appears 
to lie somewhere between 1 and 2 per million per year (Rubin 
2004) to as high as between 2.5 and 4 per million per year 
(Stewart et al 2007). The incidence of PAH is higher in cer-
tain families. Familial PAH accounts for between 6%–10% 
(Newman et al 2001) of all patients.
Underlying the development of both familial and idiopathic 
PAH are genetic mutations in the TGF-beta receptor families. 
Mutations in the gene encoding bone morphogenetic protein 
receptor type 2 (BMPR - II) have been identifi ed as being 
important in the development of PAH in most, if not all, patients 
with familial PAH (Lane et al 2000) as well as between 10% 
and 26% of patients with idiopathic PAH (Lane et al 2000).
PAH can also be seen in association with a variety of 
other conditions as described in Group 1 of the World Health 
Organization Venice classifi cation (Table 1). These associated 
conditions include connective tissue disease and especially sys-
temic sclerosis (particularly limited cutaneous scleroderma), 
portopulmonary hypertension, certain drugs and toxins, 
HIV infection, and congenital systemic to pulmonary shunts 
(Eisenmenger syndrome). It has become increasingly recog-
nized that other conditions, especially certain hematologic, 
genetic and metabolic disorders are also associated with the 
development of PAH. The role of genetic mutations in these 
associated causes of PAH remain unclear.
Nonetheless, it is evident that one genetic mutation and/
or one environmental stimulus cannot explain all forms of 
PAH. Other candidate genes that are considered relevant to 
the development of PAH include genes encoding regulating 
factors in the serotonin pathway as well as other genes related 
to TGF-beta signaling pathways.
What is clear is that PAH arises from an interplay between 
multiple genetic and environmental factors. This multi-hit 
hypothesis (Farber and Loscalzo 2004) suggests that the 
development of PAH requires primary genetic abnormalities, 
which when infl uenced by environmental stimuli lead to the 
development of clinically evident PAH.
Role of endothelin
One of the most important abnormalities in PAH is an over 
expression of endothelin-1 (ET-1). This results in abnormally 
high concentrations in pulmonary arteries (Giaid et al 1993) 
and an increase in circulating ET-1 (Humbert, Morrell et al 
2004; Rubin 2004). Upregulation of ET-1 contributes to 
smooth muscle vasoconstriction and hypertrophy as well 
as fi brosis and infl ammation. This is important in both the 
development of pulmonary arteriolar constriction and the 
secondary right ventricular hypertrophy which is seen in 
PAH. Circulating and pulmonary ET-1 concentrations are 
strongly correlated with disease severity and prognosis in 
PAH (Giaid et al 1993; Galie et al 1996; Humbert, Morrell 
et al 2004; Rubin 2004).
Synthesis of ET-1 arises from the cleavage of a 212 resi-
due precursor peptide known as pre pro ET-1, fi rst to the 38 
amino acid big ET-1, then by endothelin converting enzyme 
to the active 21 amino acid isoform.
ET-1 acts upon two receptor sub types, ET
A
 and ET
B
. 
These receptors mediate the physiological and pathological 
effects of ET-1. ET
A
 receptors are found predominantly on 
vascular smooth muscle cells and induce vasoconstriction. 
ET
B
 receptors also appear on vascular smooth muscle cells 
where they stimulate both vasoconstriction and smooth 
muscle hyperplasia (Clozel et al 1992; Neylon et al 1994). 
However, ET
B
 receptors predominate on endothelial cells 
where they stimulate the release of vasodilating and anti-
proliferative mediators such as prostacyclin (Levin 1995). 
Under physiological conditions the predominant effect of the 
ET
B
 receptor is a vasodilatory response (Levin 1995). How-
ever, in a pathological state such as PAH, the predominant 
effect of stimulation of the ET
B
 receptors is that of vasocon-
striction and vascular smooth muscle proliferation (Benigni 
and Ramuzzi 1999). Both ET
A
 and ET
B
 receptors appear to be 
important in mediating the response to endothelin of fi brosis, 
vasoconstriction and inflammation (Katwa et al 1993; 
Filep et al 1995). Furthermore, stimulation of both ET
A
 and 
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ET
B
 receptors by endothelin is important in the myocardial 
hypertrophy and myocardial fi brosis which is seen in PAH 
(Levin 1995).
Given the central role of upregulated ET -1 in the patho-
genesis of PAH, the role of ET receptor antagonists in PAH 
received greater attention. The best studied of these endo-
thelin receptor antagonists is bosentan, a dual ET
A
 and ET
B
 
receptor antagonist. More recently, the ET
A
 selective receptor 
antagonists sitaxsentan and ambrisentan have undergone 
clinical trials in PAH. The relative benefi ts of dual ET
A
 
and ET
B
 receptor antagonism versus selective ET
A
 receptor 
antagonism remains unclear. Preliminary data suggests that 
ET
A
 selective antagonism may be as effective, at least in 
idiopathic PAH and scleroderma associated PAH as dual 
ET
A
 and ET
B
 receptor antagonism (Benedict 2007).
Treatment of PAH
Conventional therapy for PAH
General measures including management of underlying or 
contributing factors, avoidance of pregnancy, early treatment 
of intercurrent respiratory infections with antibiotics and 
the use of infl uenza and anti-pneumococcal vaccines are 
recommended (Galie 2004; Rubin 2004). Oxygen is given 
for hypoxemia and diuretics are effi cacious in the treatment 
of congestive heart failure. Digoxin may be of benefi t, 
especially if the patient is in atrial fi brillation. Non steroidal 
anti infl ammatory medications and decongestant tablets 
containing pseudoephedrine are usually avoided (Galie 
2004; Rubin 2004).
Anticoagulation with warfarin is used in most of the 
patients based on single center, retrospective studies (Fuster 
et al 1984; Rich et al 1992).
Improved survival has been seen with high dose calcium 
channel blockers in the 5%–10% of patients with idiopathic 
PAH who have demonstrated acute reactivity in response to 
pulmonary vasodilator testing. The use of high dose calcium 
channel blockers is indicated in patients with WHO func-
tional class II to III who display acute reactivity and remain 
stable (Galie et al 2004).
Specifi c PAH therapies
In recent years, the development of specifi c PAH therapies 
has increased the options available to the clinician manag-
ing a patient with PAH. There are four main classes acting 
upon three main intracellular pathways (Table 2, Figure 1) 
(Humbert, Sitbon et al 2004).
These currently available specifi c PAH therapies aim to 
redress the imbalance in mediators which occur as a result 
of endothelial cell dysfunction. This imbalance consisting 
of reduced production of prostacyclin and nitric oxide and 
upregulation of ET-1 resulting in the abnormal prolifera-
tion and contraction of pulmonary smooth muscle cells via 
three pathways, all of which are potential targets for therapy 
(Figure 1 and Table 2) (Humbert, Sitbon et al 2004).
Intravenous epoprostenol (prostacyclin) was the fi rst 
effective agent to be used for the treatment of PAH, and to 
date remains the only agent that has been shown to improve 
survival in a randomized controlled trial of patients with 
(idiopathic) PAH (Barst et al 1996). Intravenous epopros-
tenol is limited by the need for a continuous intravenous infu-
sion pump with the potential problem of line sepsis. Further, 
it is limited by side effects arising from the direct effect of 
the medication including jaw pain, headaches, fl ushing and 
gastrointestinal disturbance.
The prostacyclin analogues treprostinil (which can be 
given either intravenously or by subcutaneous infusion) and 
iloprost (which can be given either through the inhaled route 
or intravenously), have also been shown to improve exercise 
capacity and WHO functional class (Olschewski et al 2002; 
Simonneau et al 2002). The current recommendation is that 
where there are alternatives, the oral prostacyclin analogue, 
beraprost, should be avoided as it is ineffective in the medium 
to long term (Galie 2004).
The phosphodiesterase-5 (PDE-5) inhibitor sildenafi l has 
been associated with improvements in WHO functional class, 
hemodynamics and exercise capacity in a placebo controlled 
trial (Galie et al 2005). The authors are aware that some 
Table 2 Specifi c PAH therapies and method of delivery
Prostacyclin/prostacyclin analogues
  - Epoprostenol iv
  - Trepostinil iv, sc or inhaled
  - Iloprost iv or inhaled
  - Beraprost oral
Endothelin receptor antagonists
 Dual ETA and ETB blockade
  - Bosentan oral
 Selective ETA blockade
  - Sitaxsentan oral
  - Ambrisentan oral
Nitric oxide/nitric oxide donors
  - Nitric Oxide inhaled
  - L-Arginine oral
Phosphodiesterase-5 inhibitors
  - Sildenafi l oral
  - Tadalafi l oral
Abbreviations: iv, intravenous, sc, subcutaneous.
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clinicians have used the PDE-5 inhibitor, tadalafi l, in selected 
patients due to availability and cost constraints but as yet 
there is no published data of its long term effectiveness.
Inhaled nitric oxide is effi cacious in lowering pulmonary 
pressures and improving hemodynamics in ventilated patients 
(Zapol et al 1994) but is generally limited to the intensive 
care unit setting and generally necessitates positive pressure 
ventilation. Prolonged nitric oxide administration can induce 
methaemoglobinemia and platelet dysfunction.
Bosentan therapy in PAH
Bosentan was the first endothelin receptor antagonist 
approved for the use of PAH.
Clinical studies have shown that in PAH, the use of bosen-
tan is associated with improved exercise capacity, WHO 
functional class, cardiopulmonary hemodynamics, quality of 
life and delayed time to clinical worsening when compared 
to placebo. Further, long term studies have demonstrated 
improved survival with the use of bosentan when compared 
to historical controls although there is no placebo controlled 
data confi rming a survival benefi t (Table 3).
Placebo-controlled pivotal studies 
and open labeled extension
In the fi rst placebo controlled study of bosentan in PAH 
(Channick et al 2001) Channick and co-authors reported on 
32 patients with either idiopathic PAH or scleroderma associ-
ated PAH who were randomly assigned to receive bosentan 
(62.5 mg taken twice daily for four weeks then 125 mg twice 
daily) or placebo for a minimum of 12-weeks. The primary 
Figure 1 Consequences of endothelial dysfunction on pulmonary vascular smooth muscle showing potential targets for therapy. Three major pathways and associated 
therapeutic targets in abnormal proliferation and contraction of smooth muscle cells are shown. Dysfunctional endothelial cells have decreased production of prostacyclin 
and endogenous nitric oxide and increased production of endothelin-1. This imbalance of mediators along with decreased production of vasoactive intestinal peptide (VIP) 
results in a condition favouring vasoconstriction and proliferation of pulmonary artery smooth muscle cells. In addition to their actions on smooth muscle, these mediators 
have other properties including antiplatelet effects of nitric oxide and prostacyclin and profi brotic and proinfl ammatory effects of endothelin. Plus signs denote an increase 
in intracellular concentration: minus signs refl ect blockage of a receptor, inhibition of an enzyme or a decrease in the intracellular concentration. (Modifi ed and published 
with permission from Humbert, Sitbon et al (2004)).
Abbreviations: cGMP cyclic guanosine monophosphate; cAMP, cyclic adenosine monophosphate.
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end point was change in exercise capacity. Secondary end 
points included change in cardiopulmonary hemodynamics, 
BORG dyspnea index, WHO functional class and withdrawal 
due to clinical worsening.
In patients given bosentan, the distance walked in 6 
minutes improved by 70 meters after 12-weeks compared 
with baseline where as in those on placebo it worsened by 
6 meters (treatment effect 76 m, p = 0.021). There was also 
a signifi cant improvement in cardiac index and reduction 
in pulmonary vascular resistance. Further, patients who 
received bosentan had improved WHO functional class and 
reduced BORG dyspnea index. Only 3 patients withdrew 
from the study from clinical worsening and all were within 
the placebo group (p = 0.033).
In 2002, Rubin and co-authors reported the results 
of a much larger placebo controlled study (Rubin et al 
2002). In this double blind study, 213 patients with either 
idiopathic PAH or PAH associated with connective tissue 
disease received either placebo or bosentan with an initial 
dose of 62.5 mg twice daily for 4-weeks followed by either 
of 2 doses of bosentan (125 or 250 mg twice daily) for a 
minimum of 12-weeks.
By week 16, the treatment effect of bosentan (improve-
ment in 6 minute walking distance in bosentan group 
minus improvement in 6 minute walk distance in placebo 
group) was 44 meters (p  0.001). Bosentan also improved 
the WHO functional class and delayed time to clinical 
worsening.
85 of the 213 patients enrolled in this study were 
included in an echocardiographic sub study (Galie et al 
2003). At baseline, patients had echocardiographic find-
ings consistent with severe PAH. Treatment effects of 
bosentan compared with placebo after 16 weeks showed 
improvements in the echocardiographic measures of car-
diac index, right ventricular function and right ventricular 
size and function and reduced frequency of pericardial 
effusion. Further, left ventricular early diastolic filling 
was improved in the bosentan group suggesting reduced 
compression of the left ventricle by a dilated and hyper-
trophied right ventricle and/or better flow to pulmonary 
veins secondary to reduced pulmonary pressure allowing 
earlier and better filling characteristics.
In all three of these studies (Channick et al 2001; Rubin 
et al 2002; Galie et al 2003) patients were in WHO functional 
class III or IV at baseline.
29 of the 32 patients enrolled in the original study 
(Channick et al 2001) received bosentan at a dose of 125 mg 
twice daily in an open labeled extension for an additional 
year. This one year follow up study (Sitbon et al 2003) found 
that improvements in 6 minute walk distance that were 
achieved with bosentan in the original study were maintained. 
41.4% of patients improved their NYHA functional class, 
whereas only 1 patient had a deterioration in functional class. 
Further, 11 patients underwent repeat right heart catheter-
ization between 8 and 22-months after commencement of 
treatment with bosentan. For these patients, cardiac index 
and PVR was signifi cantly improved compared to baseline. 
There was also a small reduction in mean pulmonary artery 
pressure, which did not reach statistical signifi cance.
Effect of bosentan on survival 
in idiopathic PAH
None of the placebo-controlled trials of bosentan in PAH 
were powered to show survival benefi t. Therefore the only 
information available regarding survival benefi t from bosen-
tan comes from comparisons with historical controls and 
National Institute of Health (NIH) registry data.
In 2005, McLaughlin and colleagues (2005) reported the 
fi rst long term survival data with bosentan in patients with 
idiopathic PAH. All patients were in WHO functional class 
III or IV at baseline. The authors reported on 169 patients 
with idiopathic PAH who received bosentan as fi rst line 
therapy for their disease. After 12 and 24-months of follow 
up, 85% and 70% of patients, respectively remained on 
bosentan monotherapy. Another 7% continued bosentan 
while receiving additional therapies.
The Kaplan-Meier survival estimate at two years was 
89% in this study compared to the predicted two years 
survival (based on historical cohorts) of 57%. At each six 
month interval, observed survival was signifi cantly better 
Table 3 Impact of bosentan therapy in patients with idiopathic 
pulmonary arterial hypertension
Parameter showing improvement Study p value
Survival McLaughlin 0.01a 
Time to clinical worsening Rubin = 0.0015
Exercise capacity (6MWDb) Rubin 0.001
 Channick = 0.021
Cardiopulmonary hemodynamics Channick 0.001 for CIc,
  PVRd and RAPe
WHO functional class Rubin = 0.04
Quality of Life Keogh <0.0001 for
  physical function
Echocardiographic parameters Galie = 0.007
Abbreviations: acompared to predicted survival based upon NIH registry;
b6MWD, six minute walk test distance; cCI, Cardiac Index; dPVR, pulmonary vascular 
resistance; eRAP, mean right atrial pressure.
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than predicted. Overall, patients receiving fi rst line bosentan 
therapy had a 5.5% annual death rate (Figure 2).
In 2005, Sitbon and colleagues (2005) compared the 
survival of 139 patients with idiopathic PAH in WHO 
functional class III who received bosentan as first line 
therapy with historical records of patients who received 
intravenous epoprostenol as f irst line therapy. After 
correcting for differences in severity at baseline, there was no 
signifi cant difference in one and two year survival between 
the two groups. This is particularly important because intra-
venous epoprostenol therapy is the only treatment that has 
been shown to improve survival in PAH in a prospective 
placebo controlled study (Barst et al 1996).
In a large single center study, Provencher and colleagues 
(2006) examined the survival of 103 consecutive patients 
with NYHA functional class III or IV idiopathic PAH 
who were treated f irst line with bosentan. Bosentan 
was prescribed at a dose of 62.5 mg twice daily for 
4-weeks followed by 125 mg twice daily. The mean duration 
of follow up was 24 ± 15-months and overall survival esti-
mates were 92, 89 and 79% at 1, 2 and 3-years respectively. 
The predicted survival at 1, 2 and 3-years, based on the equa-
tion derived from the NIH registry (D’Alonzo et al 1991) was 
71, 61 and 51% respectively. Intravenous epoprostenol was 
added in 30 patients and inhaled iloprost in an additional 6 
patients following a mean duration of exposure of bosentan 
of 12 ± 10-months. The reasons for the initiation of additional 
therapy included worsening of NYHA functional class on 
treatment, a signifi cant fall in 6 minute walk distance or 
failure of signifi cant improvement in cardiac index.
Bosentan in connective tissue 
disease associated PAH
PAH can complicate all forms of connective tissue disease. 
Most commonly it complicates systemic sclerosis (sclero-
derma) especially the limited cutaneous subtype. Depend-
ing on the criteria used, PAH can complicate up to 25% of 
patients with limited cutaneous scleroderma (Hoeper 2002). 
However, PAH can also complicate SLE, mixed connec-
tive tissue disease and less commonly, rheumatoid arthritis 
(Hoeper 2002).
Overall, the results with bosentan (or any other specifi c 
PAH therapy) have not been as impressive with scleroderma 
associated PAH when compared to idiopathic PAH. This 
most probably refl ects a different pathogenesis, older age of 
patients and that these patients tend to present later in their 
disease course (Hoeper 2002). As a result many groups are 
recommending that all patients with scleroderma regardless 
of symptomatology be screened for the presence of PAH by 
serial echocardiography and lung function (Black 2005).
Denton and colleagues (2006) analyzed the results of 
bosentan therapy for PAH related to connective tissue 
disease from the two placebo-controlled clinical trials and 
their open labeled extensions. 66 patients with connective 
tissue disease associated PAH, in WHO functional class III 
or IV were randomized to participate in the pivotal placebo 
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Figure 2 Survival in adult patients with idiopathic pulmonary arterial hypertension treated with fi rst line bosentan therapy compared to predicted survival with conven-
tional therapy according to NIH registry. (Reproduced with permission from McLaughlin et al (2005)).
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controlled studies (Channick et al 2001; Rubin et al 2002). 
44 patients received bosentan and 22 patients received 
placebo. Baseline characteristics suggested that the group 
who received bosentan had more severe disease with a 
lower 6 minute walk distance and higher PVR at baseline. 
There was a treatment effect of 22 meters favoring bosen-
tan compared with placebo (not signifi cant) although time 
to clinical worsening was delayed by bosentan, suggesting 
slower disease progression.
64 of these original 66 patients continued in an open 
labeled extension. 40 of these patients remained on bosentan 
monotherapy, one received prostanoids in addition to bosentan 
and in 23 patients, bosentan was ceased. The mean duration of 
bosentan therapy in this group of patients was 1.8 ± 0.8-years. 
Survival was 85.9% at one year and 73.4% at two years and 
of the 40 patients on bosentan monotherapy, 25% improved 
in WHO functional class by end of treatment.
Williams and co-authors (2006) reviewed the data of 
45 patients in a routine clinical setting with scleroderma 
associated PAH who received bosentan monotherapy. 
Survival in this group was 81% at one year and 71% at two 
years. This was similar to the survival reported by Girgis and 
colleagues (2005) who found an 87% one year and 79% two 
year survival for 17 patients with scleroderma associated 
PAH who received bosentan as fi rst line therapy.
Effect of bosentan on quality of life 
of patients with PAH
In an uncontrolled Australian study bosentan monotherapy 
was associated with signifi cant improvements in quality of 
life, as measured by the SF-36 questionnaire, which persisted 
for 12-months (Keogh et al 2007). Patients with idiopathic 
or familial PAH as well as those with connective tissue 
disease were included in this study. All patients were in 
WHO functional class III or IV at baseline and had not had 
previous treatment with specifi c PAH therapies. Analysis of 
a sub group of this study showed that bosentan also improved 
six minute walk distance over a 12-month period and that 
quality of life and six minute walk distance were well cor-
related although improvements in quality of life appeared to 
be a more sensitive indicator of response to treatment than 
changes in six minute walk distance (Gabbay et al 2005).
Recommendations for role of 
bosentan monotherapy in PAH
The data from the studies in idiopathic, familial and 
Scleroderma-associated PAH has led to the recommendation 
that bosentan monotherapy is indicated for patients in WHO 
functional class III in these conditions (Galie 2004). Bosentan 
also appears to be effective in patients in WHO functional 
class IV but it remains unclear if it is a preferred fi rst line 
therapy compared to intravenous epoprostenol, where there 
appears to be more evidence for intravenous epoprostenol 
therapy (Galie 2004). In patients with idiopathic or familial 
PAH who present in WHO class IV with evidence of right 
ventricular dysfunction, the authors and others recommend 
that intravenous epoprostenol be considered as fi rst line 
therapy (Galie 2004).
In those patients who are stabilized on intravenous 
epoprostenol, especially at low doses, it may be possible to 
switch them to bosentan monotherapy although this needs 
to be done with a very slow reduction of epoprostenol dose 
and concomitant monitoring (Steiner et al 2006).
Bosentan has been shown to be effective in a placebo- 
controlled trial in patients in WHO functional class II (EARLY 
Study – Actelion press release). However, at the time of 
writing this study is unpublished and regulatory authorities 
in most countries have not approved bosentan for use in this 
class of patients. Therefore its use would be limited by the 
current prohibitive costs for most individuals in WHO class 
II (see discussion on cost-effectiveness and availability).
The role of bosentan as part of combination therapy in 
PAH is discussed later in this article.
Bosentan in other forms of 
associated PAH
Most of the clinical studies of bosentan in PAH have concen-
trated on patients with idiopathic and familial PAH as well as 
those with PAH in association with connective tissue disease 
especially scleroderma. However, there is also evidence of 
the effi cacy of bosentan in PAH associated with HIV infec-
tion and PAH associated with congenital heart disease as 
well as in the pediatric population (Table 4).
In a study on the effects of bosentan on human immu-
nodefi ciency virus associated PAH, Sitbon and colleagues 
(2004) described the results of bosentan therapy given for 
16-weeks in 16 patients. In patients with HIV infection, the 
HIV-1 envelope glycoprotein 120 may stimulate the production 
of endothelin. Endothelin levels are signifi cantly elevated 
in patients with vascular complications of HIV infection. 
The authors postulated that endothelin may contribute to 
the pathogenesis of vasculopathies associated with HIV 
infection, including PAH. In this open labeled uncon-
trolled study the authors found that 6 minute walk distance 
improved by 91 meters (p  0.001) and there were signifi cant 
improvements in NYHA functional class, cardiopulmonary 
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hemodynamics, Doppler echocardiographic variables and 
quality of life. During the study, no patient died and none 
required other therapies towards their PAH. Furthermore, 
bosentan did not have a negative impact on control of HIV 
infection, nor did its use signifi cantly interact with anti-
retroviral therapy.
Congenital heart disease characterized by the develop-
ment of systemic to pulmonary shunting (eg, atrial septal 
defect, ventricular septal defect, patent ductus arteriosus) may 
lead to the development of PAH and consequent intracardiac 
right to left shunting (Eisenmenger syndrome). Galie and 
co-authors (Galie et al 2006) reported the results of a 16-week 
double blind placebo controlled study evaluating the effect 
of bosentan in Eisenmenger syndrome. 54 patients were 
randomized to receive either bosentan (n = 37) or placebo 
(n = 17). Despite theoretical concerns that vasodilator therapy 
may reduce systemic blood pressure more than pulmonary 
pressures and hence worsen right to left shunt, bosentan 
did not worsen oxygen saturations. The treatment effect of 
bosentan when compared to placebo was an increase in six 
minute walk distance of 53.1 m (p = 0.0079) and a signifi cant 
fall in PVR and mean pulmonary artery pressure.
In an open label study, Kotlyar and co-authors (Kotlyar 
et al 2006) evaluated the effects of bosentan in 23 patients 
with Eisenmenger syndrome. There was a mean duration 
of follow up of 15 ± 10-months, 57% of the patients had 
improved by at least one functional class (p = 0.016) and 
mean oxygen saturation at rest increased from 81% to 84% 
(p = 0.001). Overall, the six minute walk distance did not 
change from the baseline of 335 m.
Pulmonary hypertension may complicate chronic throm-
boembolic disease. Although chronic thromboembolic 
pulmonary hypertension (CTEPH) is a different disease 
to idiopathic PAH, with different underlying mechanisms, 
some similarities in the pathogenesis and pathology of these 
conditions exist. Pulmonary endarterectomy (PEA) surgery 
is the treatment of choice for patients with severe CTEPH 
and appropriate disease distribution (Jamieson et al 2003). 
However, a substantial proportion of patients with CTEPH 
are considered inoperable due to signifi cant distal thrombo-
embolic pathology or due to concomitant morbidity. It has 
been postulated that in patients with CTEPH who can not 
undergo PEA or in whom pulmonary hypertension persists 
following surgery, then specific PAH therapies may be 
effective.
A summary of the effects of bosentan in either inoperable 
CTEPH or persistent pulmonary hypertension after PEA 
is shown in Table 5. In summary, bosentan therapy for a 
treatment duration of up to three years has been associated 
in these open labeled studies with improvements in NYHA 
functional class, exercise capacity and cardiopulmonary 
hemodynamics (Bonderman et al 2005; Hoeper et al 2005; 
Hughes et al 2005, 2006). Further, an open labeled study 
by Musk and colleagues (2006) found that treatment with 
Bosentan in CTEPH was associated with improvements in 
exercise capacity and cardiopulmonary hemodynamics that 
were similar to the improvements seen in a similarly treated 
group of patients with idiopathic PAH and with a trend to 
greater improvements than those seen with scleroderma 
associated PAH in the same center.
A multi center randomized trial in patients with inop-
erable CTEPH (BENEFIT), which includes a four month 
bosentan/placebo controlled phase, found that bosentan was 
associated with reduced PVR and prolonged time to clinical 
worsening when compared to placebo but there was no dif-
ference in exercise capacity (as measured by 6 minute walk 
test) in the two groups (Jais et al 2007). The results from 
the open labeled extension are awaited to help determine if 
exercise capacity improves in the longer term and this may 
help to clarify the role of bosentan in CTEPH.
Pediatrics
The data on effi cacy and safety of bosentan in pediatric 
patients with PAH is not as extensive as that in adults. Barst 
and colleagues (2003) describe three different dosing regimes 
of bosentan in 19 pediatric patients stratifi ed for body weight 
Table 4 Impact of bosentan therapy in pulmonary arterial 
hypertension (PAH) subgroups
PAH sub-group Parameter showing Study
 improvement 
Scleroderma associated Survivala Denton, Williams,
PAH time to clinical Girgis,
 worsening Denton,
 6-MWDb Denton,
 WHO functional class Denton,
 Quality of life Keogh
HIV associated PAH 6-MWDb Sitbon,
 WHO functional class Sitbon,
 Hemodynamics Sitbon,
 Quality of life Sitbon
Eisenmenger syndrome 6-MWDb Galie,
 WHO functional class Galie,
 Hemodynamics Galie
Pediatric PAH Survivala Rosenzweig,
 WHO functional class Rosenzweig,
 Hemodynamics Barst, Rosenzweig
Note: acompared to historical data.
Abbreviation: b6-MWD, six minute walk test distance.
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and epoprostenol use. They found that the pharmacokinet-
ics of bosentan in pediatric patients with PAH and healthy 
adults were similar and the treatment with bosentan resulted 
in hemodynamic improvement. Rosenzweig and colleagues 
(2005) described the use of bosentan in 86 children with 
either idiopathic PAH or PAH associated with congenital 
heart disease or connective tissue disease. Median exposure 
to bosentan was 14-months. In 46% of the patients, WHO 
functional class improved and there was a signifi cant fall in 
mean pulmonary artery pressure and PVR. Kaplan-Meier 
survival estimates at one and two years were 98% and 91% 
respectively. The authors concluded that bosentan, with 
or without concomitant epoprostenol therapy, is safe and 
effi cacious for the treatment of PAH in children.
Dose of bosentan in treatment 
of PAH
The large placebo controlled study of two bosentan dosing 
regimes in adult patients with PAH (Rubin et al 2002) 
found that the dose of bosentan of 62.5 mg twice daily for 
4-weeks followed by 125 mg twice daily was associated 
with equivalent effi cacy as the higher dose of 250 mg 
twice daily with fewer side effects. Since that study, the 
dose of bosentan was 62.5 mg twice daily for 4-weeks 
followed by 125 mg twice daily, and this dosing regimen 
has been considered standard and hence been used in all 
future studies of adults with Bosentan in PAH. The dose of 
bosentan in children is dependent upon age and weight and 
has been described by Barst et al (2003) and Rosenzweig 
et al (2005).
Recommended dosing regimens for adults and children 
are summarized in Table 6.
Safety and tolerability
The most signifi cant adverse event in patients on bosentan 
treatment is the potential development of abnormal hepatic 
function and specifi cally a rise in hepatic amino transaminases. 
The basis of this is uncertain but it has been postulated that it is 
related to bosentan interfering with biliary salt excretion. The 
incidence of abnormal increase in hepatic amino transaminase 
levels to greater than three times normal varies from 9.7% in 
the largest placebo controlled study (although there was only 
a 4% incidence in the group receiving 125 mg twice daily of 
bosentan) (Rubin et al 2002) to as high as 14.9% in the longer 
observational studies (McLaughlin et al 2005).
Post marketing surveillance with Bosentan through 
the internet based (Trax) system has observed the use of 
bosentan in 4994 patients enrolled between May 2002 and 
November 2004. Median exposure over the two year obser-
vation period was approximately 35-weeks in patients with 
idiopathic PAH. The frequency of abnormal elevations in 
hepatic transaminase (ALT/AST) was approximately 8.4%. 
These elevations are reversible on stopping bosentan. Liver 
enzyme changes typically occur within the fi rst six weeks of 
treatment initiation although it appears that they can occur at 
any time after the initiation of bosentan treatment.
As a result, liver amino transaminase levels must be 
measured prior to initiation of treatment and monthly there-
after. If elevated amino transaminase levels are seen, then 
changes in the monitoring and treatment of these patients are 
made according to a well defi ned protocol (Table 7). If liver 
amino transaminase elevations are accompanied by clinical 
symptoms of liver injury or an elevation in bilirubin greater 
than or equal to two times the upper limit of normal then 
treatment should be stopped.
Table 5 Impact of bosentan therapy in chronic thromboembolic 
pulmonary hypertension (CTEPH)
Study Indication n Treatment  Parameter showing
   duration improvement
Bonderman Inoperable  16 6 months NYHA functional class
et al 2005 CTEPH   6-MWDa
Hoeper,  Inoperable  19 3 months Hemodynamics
Kramm CTEPH   6-MWD
et al 2005    
Hughes Inoperable  20 3 months Hemodynamics
 CTEPH/   6-MWD
 Persistent    
 PH after   
 surgery   
Hughes Inoperable  47 1 year WHO functional class
 CTEPH/   Hemodynamics
 Persistent    6-MWD
 PH after   
 surgery   
Abbreviation: a6-MWD, six minute walk test distance.
Table 6 Recommended dosing regimens for bosentan in adults 
and children
  Starting dose Maintenance dose
  (1st 4-weeks) (Week 5 onwards)
Adults (12 years of age)
 Bodyweight  40 kg 62.5 mg twice daily 125 mg twice daily
 Bodyweight  40 kg 62.5 mg twice daily 62.5 mg twice daily
Children (12 years of age)
 Bodyweight 10 kg 15.6 mg daily 15.6 mg twice daily
 Bodyweight 10–20 kg 31.25 mg daily 31.25 mg twice daily
 Bodyweight 20–40 kg 31.25 mg twice daily 62.5 mg twice daily
 Bodyweight 40 kg 62.5 mg twice daily 125 mg twice daily
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Bosentan treatment is associated with a fall in hemoglobin 
and hematocrit in up to 10% of patients. It is recommended 
that hemoglobin concentrations be checked after one and 
three months and every three months thereafter. The cause 
of this reduced hemoglobin with bosentan is unclear but in 
part may be related to dilutional effects as a result of fl uid 
retention, in part as a result of the effects of ET
B
 receptor 
blockade in the renal glomerulus.
Bosentan is teratogenic in rats and is contraindicated in 
pregnancy. It is not recommended to be used by lactating 
women. Other side effects such as headaches, fl ushing and 
syncope may occur due to the effects of bosentan on the sys-
temic vasculature and associated systemic vasodilatation.
There is limited data on the safety of suddenly stopping 
bosentan. In an open labeled Australian study (Keogh et al 
2007), 2% of patients died within 1-month of stopping 
bosentan. These were patients who were deteriorating despite 
therapy and it is unclear if their death refl ected the natural his-
tory of the disease rather than due to bosentan withdrawal.
Drug interactions
Bosentan is an inducer of the cytochrome P450 isoenzymes 
CYP2C9 and CYP3A4. Consequently, plasma concentrations 
of drugs metabolized by these isoenzymes will be decreased 
when bosentan is co-administered. Because estrogens and 
progestogens are partially metabolized by these isoenzymes, 
there is a possibility of failure of contraception when bosen-
tan is co-administered with oral contraceptive medication.
The use of bosentan when co-administered with warfarin 
may be associated with reduced plasma concentrations of 
warfarin. In the large placebo controlled study (Rubin et al 
2002) the frequency of changes in warfarin dose was similar 
amongst bosentan and placebo treated patients. However, 
personal experience suggests that the warfarin dose often 
needs to be increased when bosentan is co-administered. At 
the very least we would recommend intensifi ed monitoring of 
international normalized ratio (INR) for patients on warfarin 
during bosentan initiation and up titration periods.
Co-administration of bosentan and cyclosporin or tacro-
limus is contraindicated because of signifi cant reduction in 
the effectiveness of these immunosuppressive agents. Like-
wise concomitant glibenclamide (glyburide in the United 
States) administration is contraindicated both because of an 
increased risk of elevated hepatic amino transaminase levels 
as well as a signifi cant increase in glibenclamide concentra-
tion during concomitant use.
Bosentan as part of combination 
therapy
The newer specifi c PAH therapies such as bosentan have 
resulted in signifi cant improvements in exercise capacity, 
cardiopulmonary hemodynamics and survival. However, 
responses are variable and in many patients, disease pro-
gresses despite therapy. As a result an increasing number 
of patients are being considered for combination therapy 
(Hoeper and Dinh-Xuan 2004).
Current therapies in the treatment of PAH act on the 
three intracellular pathways, endothelin, nitric oxide and 
prostacyclin, known to be abnormal in PAH (Figure 1). 
A logical extension therefore is to use a combination of two 
or more therapies each acting in synergy through a different 
pathway (Hoeper and Dinh-Xuan 2004).
The combination of bosentan and sildenafi l is of particular 
interest because both are oral agents, which are generally 
well tolerated. Hoeper and colleagues (2004) reported the 
clinical course of 9 patients with severe idiopathic PAH, 
in whom bosentan caused transient clinical improvement, 
eventually followed by a decline in exercise tolerance, who 
then received adjunct treatment with sildenafi l.
Bosentan was associated with an initial improvement in 
six minute walk test distance but this effect was not sustained. 
After an interval of 11 ± fi ve months of bosentan treatment, 
sildenafi l was added. Three months later, the six minute 
Table 7 Monitoring and management of elevated liver enzymes 
for patients treated with bosentan
Liver function monitored at least monthly (fortnightly after ini-
tiation or dose escalation), with dose modifi cation (if required) 
based on following protocol:
ALT/AST levels* Treatment and monitoring recommendations §
3 × ULN  Repeat
 Monitor fortnightly attend to potential other
 causes of elevation eg, concomitant medications,
 alcohol, biliary abnormalities
3 and 5 × ULN Repeat
 Reduce to starting dose or stop bosentan monitor
 ALT/AST at least fortnightly re-introduce at 
 starting dose if pre-treatment levels are reached
5 and 8 × ULN Repeat
 Stop bosentan monitor ALT/AST at least fortnightly
 Re-introduce at starting dose if pre-treatment
 levels are reached
8 × ULN Repeat
 Stop permanently
Note:*ALT, alanine transaminase; § Bosentan should be stopped if any elevation  
3 × ULN in AST/ALT levels occur in association with rise in bilirubin to  2 × ULN 
and/or symptoms of liver dysfunction.
Abbreviations: AST, aspartate transaminase; ULN, Upper limit of normal
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walk test distance had increased by a mean of 115 m and 
this improvement persisted for a median follow up of nine 
months (Hoeper et al 2004).
In a small German study, involving eleven patients with 
different forms of pulmonary hypertension, but including 
idiopathic PAH and congenital heart disease, Lunze and 
co-authors (Lunze et al 2006) found that the combination of 
sildenafi l and bosentan was associated with improvements 
in exercise capacity and reduction in mean pulmonary artery 
pressure. They found that the combination was well tolerated 
although one patient died suddenly for reasons that are not 
evident in the paper.
There is a pharmacological interaction between bosentan 
and sildenafi l in that bosentan decreases the plasma con-
centration of sildenafi l and sildenafi l increases the plasma 
concentration of bosentan when they are co-prescribed in 
PAH (Paul et al 2005). However, this interaction does not 
appear to be associated with signifi cant problems and the 
combination of bosentan and sildenafi l does not appear to 
be associated with an increased risk of abnormal elevation 
of liver transaminases when compared to the use of bosentan 
alone (Hoeper, Kiely et al 2005).
Humbert and colleagues reported the results of a 
double blind placebo controlled prospective study in which 
33 patients with PAH were commenced on intravenous 
epoprostenol treatment and were randomized to receive 
either bosentan or placebo. Hemodynamics, exercise capac-
ity and functional class improved in both groups at week 16 
and in the combination treatment group there was a trend 
for a greater (although non signifi cant) improvement in all 
measured hemodynamic parameters. The authors concluded 
that this was an essentially negative study and that additional 
information was needed to evaluate the risk/benefi t ratio 
of combined bosentan and epoprostenol therapy in PAH 
(Humbert, Barst et al 2004).
McLaughlin and colleagues (2006) reported the 
results of a randomized multi center double blind trial in 
67 patients with PAH (55% idiopathic PAH, 45% associ-
ated PAH, 94% NYHA class III ), in which inhaled iloprost 
(5 mcgm) or placebo was added to stable monotherapy 
with bosentan for 12-weeks. There was a treatment effect 
of adding iloprost of an increase in six minute walk dis-
tance of 26 m (p = 0.051). The addition of iloprost was 
also associated with signifi cant improvement in NYHA 
functional class and increased time to clinical worsening 
when compared with placebo. The authors concluded that 
within the limitations of the relatively small sample size, 
the addition of inhaled iloprost in patients with PAH with 
reduced exercise capacity on bosentan monotherapy was 
both safe and effi cacious.
Goal oriented (combination) 
therapy
It has become increasingly clear that where it has been used, 
combination therapy with two or more agents has been asso-
ciated with improvements in exercise capacity and functional 
class in patients with PAH. The question of which combina-
tion should be used and when remains unclear (Hoeper and 
Dinh-Xuan 2004).
Some authors have recommended adding increasing 
number of agents in combination, when specifi c treatment 
goals have not been met. Hoeper and colleagues have shown 
(Hoeper, Markevych et al 2005) that this goal oriented 
approach to therapy, based on achieving set functional cri-
teria, has been associated with improved survival and less 
requirement for transplantation than in a historical cohort 
treated with monotherapy alone.
In summary, whilst ongoing studies are required in 
assessing bosentan as part of combination therapy it appears 
that such a strategy can be associated with improvements in 
exercise capacity, functional class and possibly survival in 
patients with PAH (Hoeper et al 2004; Hoeper and Dinh-
Xuan 2004; Humbert, Barst et al 2004; Hoeper, Kiely et al 
2005; Hoeper, Markevych et al 2005; Paul et al 2005; Lunze 
et al 2006; McLaughlin et al 2006).
Atrial septostomy and lung 
transplantation
Atrial septostomy and lung transplantation are potential life-
saving therapies, which are reserved for a small number of 
patients who are deemed likely to benefi t from them and in 
whom the selective PAH therapies discussed above are inef-
fective. A detailed discussion of these therapies is beyond the 
scope of this article and the reader is referred elsewhere for 
a detailed discussion of surgical therapies in PAH including 
atrial septostomy and lung transplantation (ASTP et al 1998; 
Doyle et al 2004).
Sitbon and colleagues have described the criteria that 
they use to categorize patients as failing to respond to 
3-months of intravenous epoprostenol therapy (Sitbon et al 
2002). These patients were then considered for lung trans-
plantation. Although no such criteria have been described for 
bosentan, alone or in combination with other agents, the reader 
is referred to the general principles prescribed by Sitbon and 
others when considering timing for referral for transplantation 
(ASTP et al 1998; Sitbon et al 2002; Doyle et al 2004).
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Cost-effectiveness and access to 
specifi c PAH therapies
There is limited data on the cost-effectiveness of bosentan 
or other specifi c PAH therapies (Wlodarczyk et al 2006), 
despite the importance that health authorities appropriately 
place on such data. These drugs are generally expensive 
and availability is limited in most countries. Almost all of 
the patients in the previously described clinical trials were 
in WHO (or NYHA) class III or IV at enrolment. This may 
refl ect the resistance of some health authorities to subsidise 
therapy for patients in other functional classes.
It is our view that part of the responsibility of health care 
professionals is to advocate for reduced costs and greater avail-
ability of these therapies especially in developing countries.
Summary
The dual endothelin receptor antagonist bosentan given at a 
dose (in adults) of 62.5 mg twice daily for four weeks followed 
by 125 mg twice daily is a safe and effi cacious therapy in PAH. 
The use of bosentan as part of a comprehensive management 
plan has resulted in improvements in exercise capacity, func-
tional class, quality of life and survival. Patients require regular 
monthly monitoring of liver function tests and clear guidelines 
are in place in terms of reducing or stopping bosentan therapy 
depending upon the results of these liver function tests. Because 
of bosentan’s ability to induce the cytochrome p450 family, pa-
tients must be advised to contact their treating physician before 
initiation of other prescription medicines including oral conta-
raceptives and antibiotics. Bosentan has been extensively used 
as monotherapy in PAH especially in patients with idiopathic 
PAH and scleroderma associated PAH but also appears to be 
effi cacious in other forms of pulmonary hypertension including 
other connective tissue disease associated PAH, HIV associated 
PAH and Eisenmenger syndrome as well as in selected cases of 
chronic thromboembolic pulmonary hypertension. Bosentan may 
also have a role as part of combination therapy in patients who 
have responded sub optimally to monotherapy.
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